MNKD Enrolls Patients for Afrezza - Analyst Blog


MannKind Corporation ( MNKD ) recently announced the completion of the patient recruitment process for its phase III clinical studies (study 171 and study 175) of Afrezza. Afrezza is an ultra rapid-acting mealtime insulin therapy being developed for the treatment of type I and type II diabetes.

The first study (171) is evaluating the candidate in patients suffering from type I diabetes. In this study, patients are randomized to one of three arms: a control arm, in which patients utilize injected rapid-acting insulin at mealtimes, or one of two Afrezza arms, with patients either on MedTone or the next-generation inhalers.

The second study (175) is evaluating Afrezza in patients suffering from type II diabetes. This study will assess Afrezza using the next-generation inhaler in patients who are inadequately controlled on metformin, with or without a second or third oral medication. Further, patients will be randomized to either Afrezza or placebo.

MannKind believes that it can complete both trials in the second quarter of 2013 and submit a new drug application by the third quarter of 2013.

Notably, in January 2011, MannKind had received a second complete response letter (CRL) from the US Food and Drug Administration (FDA) for Afrezza. The FDA asked the company to conduct these two phase III trials with the next-generation inhaler.

Following the receipt of the second CRL, MannKind trimmed its workforce by approximately 41% and cancelled its insulin supply deal with N.V. Organon, a subsidiary of Merck & Co. Inc . ( MRK ).

Our Recommendation

Currently, we have a Neutral recommendation on MannKind, which carries a Zacks #3 Rank (short-term Hold rating). MannKind is primarily dependent on the successful development of Afrezza and we expect investor focus to remain on the same.

MANNKIND CORP (MNKD): Free Stock Analysis Report
MERCK & CO INC (MRK): Free Stock Analysis Report

To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: CRL , MNKD , MRK

More from

Related Videos



Most Active by Volume

  • $10.69 ▲ 4.91%
  • $29.59 ▲ 5.94%
  • $16.36 ▼ 0.49%
  • $2.3701 ▲ 3.95%
  • $112.9573 ▲ 0.03%
  • $5.97 ▲ 4.19%
  • $9.32 ▲ 5.19%
  • $28.385 ▲ 2.40%
As of 8/28/2015, 11:38 AM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by